AK120 clinical trials
Also written AK120.
How each study uses AK120 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the AK120 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AK120
- 6
Studies by the year they started
7 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses AK120 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)Not yet recruitingPhase 2AkesoNCT06756126Written as AK120
- A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic DermatitisRecruitingPhase 3AkesoNCT06383468Written as AK120
- A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic DermatitisCompletedPhase 2AkesoNCT06700499Written as AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)
- A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic DermatitisCompletedPhase 1/2AkesoNCT06035354Written as AK120
- Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic DermatitisTerminatedPhase 2Akesobio Australia Pty LtdNCT05048056Written as AK120
- A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic DermatitisCompletedPhase 2AkesoNCT06092762Written as AK120
- A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe AsthmaTerminatedPhase 2AkesoNCT05155020Written as AK120